NYSE American - Delayed Quote USD

Lineage Cell Therapeutics, Inc. (LCTX)

0.4400
-0.0300
(-6.38%)
At close: May 9 at 4:00:00 PM EDT
0.4381
-0.00
(-0.43%)
After hours: May 9 at 6:22:52 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
9,499
9,499
8,945
14,703
3,896
Cost of Revenue
334
334
671
728
1,426
Gross Profit
9,165
9,165
8,274
13,975
2,470
Operating Expense
30,643
30,643
33,007
36,495
51,681
Operating Income
-21,478
-21,478
-24,733
-22,520
-49,211
Net Non Operating Interest Income Expense
1,715
1,715
1,629
829
2
Other Income Expense
1,181
1,181
-178
-4,121
5,939
Pretax Income
-18,582
-18,582
-23,282
-25,812
-43,270
Tax Provision
0
0
-1,803
541
0
Net Income Common Stockholders
-18,609
-18,609
-21,486
-26,273
-43,019
Diluted NI Available to Com Stockholders
-18,609
-18,609
-21,486
-26,273
-43,019
Basic EPS
-0.10
-0.09
-0.12
-0.15
-0.26
Diluted EPS
-0.10
-0.09
-0.12
-0.15
-0.26
Basic Average Shares
183,898
200,193
172,663
169,792
164,502
Diluted Average Shares
183,898
200,193
172,663
169,792
164,502
Total Operating Income as Reported
-21,478
-21,478
-24,733
-22,520
-49,211
Total Expenses
30,977
30,977
33,678
37,223
53,107
Net Income from Continuing & Discontinued Operation
-18,609
-18,609
-21,486
-26,273
-43,019
Normalized Income
-20,460
-20,460
-20,821.7581
-24,717.4900
-47,472
Interest Income
1,715
1,715
1,629
829
2
Net Interest Income
1,715
1,715
1,629
829
2
EBIT
-21,478
-21,478
-24,733
-22,520
-49,211
EBITDA
-20,869
-20,869
-24,041
-21,793
-48,338
Reconciled Cost of Revenue
334
334
671
728
1,426
Reconciled Depreciation
609
609
692
727
873
Net Income from Continuing Operation Net Minority Interest
-18,609
-18,609
-21,486
-26,273
-43,019
Total Unusual Items Excluding Goodwill
1,851
1,851
-720
-1,969
4,453
Total Unusual Items
1,851
1,851
-720
-1,969
4,453
Normalized EBITDA
-22,720
-22,720
-23,321
-19,824
-52,791
Tax Rate for Calcs
0
0
0.0001
0.0002
0
Tax Effect of Unusual Items
0
0
-55.7581
-413.4900
0
12/31/2021 - 3/5/1992

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GERN Geron Corporation
1.1800
-6.35%
 
CLDX Celldex Therapeutics, Inc.
18.33
-6.10%
 
VCEL Vericel Corporation
41.73
-0.33%
 
PASG Passage Bio, Inc.
0.3292
-5.02%
 
FATE Fate Therapeutics, Inc.
1.0400
+0.97%
 
NKGN NKGen Biotech, Inc.
0.1711
+3.70%
 
SER Serina Therapeutics, Inc.
5.63
-2.01%
 
PCSA Processa Pharmaceuticals, Inc.
0.2390
-12.77%
 
ADAP Adaptimmune Therapeutics plc
0.2926
-2.47%
 
BLRX BioLineRx Ltd.
3.1700
-0.94%